HBM Healthcare Investments - Strong results show success of strategy
HBM Healthcare Investments (HBMN) has reported extremely strong results for the first half of FY19 (to 30 September), with net earnings of CHF177m. While market conditions have turned negative in October, HBMN’s portfolio of private investments (c 36% of the total) and a market hedge covering c 20% of the listed portfolio should help to limit NAV volatility if the sell-off is prolonged. Results have been buoyed by good clinical data and a number of successful IPOs from the private portfolio, and HBMN’s managers are focused on finding new private opportunities to replace those now in the public portfolio. Ten new investments in H119 were diversified by clinical focus and geography (US, Europe and Asia). HBMN’s shares have re-rated substantially over the past year, arguably as a result of the ongoing evidence of successful execution of its strategy, as well as the high distribution policy (c 5% of NAV paid out each year).HBM Healthcare Investments is a holding company. Through its subsidiaries, Co. is engaged in the acquisition, holding and sale equity interests in companies in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas. Co.'s portfolio includes approximately 25 companies.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.